Immunotherapy cancer trials presented to key opinion leaders

Immodulon recently met with some of the world’s most renowned oncologists to present their forthcoming trials for immunotherapy treatment, IMM-101. Their feedback has been extremely positive and allows Immodulon to move forward with the planning of a pivotal trial, for launch next year, as well as additional exploratory investigations of IMM-101 in combination with other treatments to begin later this year.

IMM-101 is a naturally derived medical treatment that helps the body’s immune system to recognise and control cancer. It works in combination with other anti-cancer treatments to improve the overall outcome for patients, and does not add to toxicity levels in the body. Clinical studies indicate that IMM-101 has a potentially transformational impact on survival rates for cancer.

Immodulon presented to the following experts at ESMO in Barcelona, who have all indicated they are supportive of the trials, as well as Immodulon’s work in immunotherapy research:

• Professor David Cunningham, Royal Marsden Hospital, London
• Professor Michel Ducreux, Institut Gustave Roussy, Paris
• Professor Jean-Yves Blay, Universite Claude Bernard, Lyon
• Professor Eileen O'Reilly, Memorial Sloan-Kettering Cancer Center, New York
• Professor Margaret Tempero, University of California San Francisco
• Dr Harpreet Wasan, Hammersmith Hospital, Imperial College London
• Dr Andrew Gaya, Guy’s & St Thomas’ Hospitals, London
• Dr Aurelien Marabelle, Institut Gustave Roussy, Paris
• Dr Anna-Mary Young, St George’s Hospital, London
• Dr Noreen Starling, Royal Marsden Hospital, London

Professor David Cunningham, Consultant Medical Oncologist at the Royal Marsden said, “Immodulon is breaking new ground in the treatment of cancer into immunotherapy. I am delighted to have accepted the role of Chief Investigator in their forthcoming trials in this exciting new field.”

Immodulon’s Chairman, Charles Akle said, “We are immensely proud to have had such positive feedback on our study designs from some of the best and brightest minds in oncology. Immodulon will use this approval to move into Phase III trials and bring IMM-101 to market in the most efficient and affordable way.”

Source: Immodulon